Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
The OncLive Insider app is live!
CME Opportunities
Specialty
View More
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
News
OncClub
All Oncology News
OncClub
All Oncology News
Media
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Insights
MedNews Week
OncChats
OncLive News Network®
OncLive TV
Peer Exchange
Podcasts
Rapid Readouts
Conferences
Conference Coverage
Conference Listing
Conference Coverage
Conference Listing
Events
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Giants of Cancer Care
CME/CE
Scientific Interchanges
State of the Science Summit / IPC
National Fellows Forum
Webinars
Partners
Publications
Resources
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Consensus Viewpoints
OncLive App
Interactive Tools
Sponsored
Biomarker Consortium
Subscribe
Search
Spotlight
The OncLive Insider app is live!
CME Opportunities
Specialty
See All >
Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer
Immuno-Oncology | Specialty
home
Content Type
Emerging Agents for Treatment of Advanced HER2+ BC
January 22nd 2020
ATEMPT Trial: Stage I HER2+ Breast Cancer
January 22nd 2020
APHINITY Trial: Adjuvant HER2-Targeted Therapy in HER2+ BC
January 22nd 2020
Approaching HER2 Testing in Breast Cancer
January 22nd 2020
Hormone Receptor-Positive mBC: Neoadjuvant Therapy
January 22nd 2020
CtDNA Testing in Hormone Receptor-Positive mBC
January 22nd 2020
CDK4/6 Inhibition in Hormone Receptor-Positive mBC
January 22nd 2020
Strategies for Hormone Receptor-Positive Metastatic BC
January 22nd 2020
HER2+ Breast Cancer: Future Treatment Landscape
January 11th 2020
Practical Advice on Treating HER2+ Metastatic Breast Cancer
January 11th 2020
Targeting HER2 Outside of Breast Cancer
January 11th 2020
Combining Anti-HER2 Agents With Immunotherapy for HER2+ mBC
January 11th 2020
Emerging Agents for HER2+ mBC: Targeted Therapeutics
January 11th 2020
Emerging Agents for HER2+ mBC: HER2CLIMB and SOPHIA Trials
January 11th 2020
Evolving Role of Trastuzumab Deruxtecan in HER2+/HER2-Low mBC
January 11th 2020
HER2+ mBC: Addressing ILD in the DESTINY-Breast01 Study
January 11th 2020
HER2+ mBC: Study Design and Results of DESTINY-Breast01
January 11th 2020
HER2+ Breast Cancer: Evolution of Antibody-Drug Conjugates
January 11th 2020
Unmet Needs in the Management of HER2+ mBC
January 11th 2020
Treatment Strategies for Relapsed/Refractory HER2+ mBC
January 11th 2020
NEXT PAGE
<
1
...
49
50
51
52
53
54
55
56
57
...
203
>
PREVIOUS PAGE